ProPhase Labs, Inc. Income (Loss) from Continuing Operations, Per Basic Share
ProPhase Labs, Inc. (PRPH) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.22 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2026-08-19
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-06-30 was -$0.22.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2026-03-31 was -$0.42.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-09-30 was -$0.16.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2025-06-30 was -$1.08.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for fiscal 2025 was -$2.75.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for fiscal 2024 was -$24.76.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for fiscal 2023 was -$0.95.
- ProPhase Labs, Inc. income (loss) from continuing operations, per basic share for fiscal 2021 was $0.41.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 12 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.22 10-Q · filed 2026-08-19 | -$0.62 10-Q · filed 2026-08-19 | ||||||
| 2026-03-31 | -$0.42 10-Q/A · filed 2026-07-09 | -$0.43 10-Q · filed 2026-06-30 | ||||||
| 2025-12-31 | -$2.75 10-K · filed 2026-06-01 | |||||||
| 2025-09-30 | -$0.16 10-Q · filed 2025-11-19 | -$0.41 10-Q · filed 2025-11-19 | ||||||
| 2025-06-30 | -$1.08 10-Q · filed 2026-08-19 | -$0.11 10-Q · filed 2025-08-13 | -$2.38 10-Q · filed 2026-08-19 | -$0.24 10-Q · filed 2025-08-13 | ||||
| 2025-03-31 | -$1.33 10-Q/A · filed 2026-07-09 | -$0.13 10-Q · filed 2025-05-20 | ||||||
| 2024-12-31 | -$24.76 10-K · filed 2026-06-01 | -$2.42 10-K · filed 2025-04-01 | ||||||
| 2024-09-30 | -$0.26 10-Q · filed 2025-11-19 | -$0.85 10-Q · filed 2025-11-19 | ||||||
| 2024-06-30 | -$0.29 10-Q · filed 2025-08-13 | -$0.59 10-Q · filed 2025-08-13 | ||||||
| 2024-03-31 | -$0.32 10-Q · filed 2025-05-20 | |||||||
| 2023-12-31 | -$0.95 10-K · filed 2025-04-01 | |||||||
| 2021-12-31 | $0.41 10-K · filed 2022-03-31 | |||||||
| 2020-12-31 | -$0.20 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | -$0.05 10-Q · filed 2020-11-19 | -$0.11 10-Q · filed 2020-11-19 | ||||||
| 2019-12-31 | -$0.27 10-K · filed 2021-03-31 | |||||||
| 2019-09-30 | -$0.04 10-Q · filed 2020-11-19 | -$0.23 10-Q · filed 2020-11-19 | ||||||
| 2018-12-31 | -$0.14 10-K · filed 2019-03-26 | |||||||
| 2018-09-30 | -$0.08 10-Q · filed 2019-11-12 | -$0.10 10-Q · filed 2019-11-12 | ||||||
| 2018-06-30 | -$0.02 10-Q · filed 2018-08-20 | -$0.02 10-Q · filed 2018-08-20 | ||||||
| 2018-03-31 | $0.00 10-Q/A · filed 2018-08-20 | |||||||
| 2017-12-31 | -$0.14 10-K · filed 2019-03-26 | $0.92 10-K · filed 2018-03-28 | ||||||
| 2017-09-30 | -$0.03 10-Q · filed 2018-11-14 | -$0.05 10-Q · filed 2017-11-13 | -$0.13 10-Q · filed 2018-11-14 | $0.88 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | -$0.06 10-Q/A · filed 2018-08-20 | -$0.09 10-Q · filed 2017-08-11 | -$0.10 10-Q/A · filed 2018-08-20 | $0.91 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | -$0.04 10-Q/A · filed 2018-08-20 | $0.99 10-Q · filed 2017-05-15 | ||||||
| 2016-12-31 | -$0.24 10-K/A · filed 2018-08-20 | |||||||
| 2016-09-30 | -$0.05 10-Q/A · filed 2018-08-20 | $0.01 10-Q · filed 2016-11-14 | -$0.20 10-Q/A · filed 2018-08-20 | -$0.13 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | -$0.08 10-Q/A · filed 2018-08-20 | -$0.06 10-Q · filed 2016-08-11 | -$0.15 10-Q/A · filed 2018-08-20 | -$0.14 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | -$0.08 10-Q/A · filed 2018-08-20 | |||||||
| 2015-12-31 | -$0.13 10-K/A · filed 2018-08-20 | -$0.22 10-K · filed 2016-03-29 | ||||||
| 2015-09-30 | $0.04 10-Q · filed 2016-11-14 | -$0.14 10-Q · filed 2016-11-14 | ||||||
| 2015-06-30 | -$0.10 10-Q · filed 2016-08-11 | -$0.18 10-Q · filed 2016-08-11 | ||||||
| 2015-03-31 | -$0.09 10-Q · filed 2016-05-13 | |||||||
| 2014-12-31 | -$0.47 10-K · filed 2016-03-29 | |||||||
| 2014-09-30 | -$0.18 10-Q · filed 2015-11-13 | -$0.42 10-Q · filed 2015-11-13 | ||||||
| 2014-06-30 | -$0.19 10-Q · filed 2015-08-12 | -$0.24 10-Q · filed 2015-08-12 | ||||||
| 2013-12-31 | $0.04 10-K · filed 2015-03-27 | $0.03 10-K · filed 2016-03-29 | ||||||
| 2013-09-30 | $0.08 10-K · filed 2015-03-27 | |||||||
| 2013-06-30 | -$0.11 10-K · filed 2015-03-27 | |||||||
| 2013-03-31 | $0.02 10-K · filed 2015-03-27 | |||||||
| 2012-03-31 | -$0.05 10-Q · filed 2013-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |